company background image
524735 logo

Hikal BSE:524735 Stock Report

Last Price

₹382.70

Market Cap

₹45.5b

7D

10.1%

1Y

29.6%

Updated

20 Jan, 2025

Data

Company Financials +

524735 Stock Overview

Manufactures and sells various chemical intermediates, specialty chemicals, and active pharma ingredients to pharmaceutical, animal health, biotech, crop protection, and specialty chemicals companies in India, the United States, Canada, Europe, South East Asia, and internationally. More details

524735 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth1/6
Past Performance1/6
Financial Health4/6
Dividends4/6

My Notes

Capture your thoughts, links and company narrative

Hikal Limited Competitors

Price History & Performance

Summary of share price highs, lows and changes for Hikal
Historical stock prices
Current Share Price₹382.70
52 Week High₹464.50
52 Week Low₹260.65
Beta1.27
1 Month Change1.02%
3 Month Change9.70%
1 Year Change29.55%
3 Year Change-0.12%
5 Year Change193.59%
Change since IPO37,338.16%

Recent News & Updates

Recent updates

Shareholder Returns

524735IN PharmaceuticalsIN Market
7D10.1%-1.8%-0.3%
1Y29.6%26.8%10.6%

Return vs Industry: 524735 exceeded the Indian Pharmaceuticals industry which returned 26.8% over the past year.

Return vs Market: 524735 exceeded the Indian Market which returned 10.6% over the past year.

Price Volatility

Is 524735's price volatile compared to industry and market?
524735 volatility
524735 Average Weekly Movement6.2%
Pharmaceuticals Industry Average Movement6.0%
Market Average Movement6.3%
10% most volatile stocks in IN Market9.1%
10% least volatile stocks in IN Market4.2%

Stable Share Price: 524735 has not had significant price volatility in the past 3 months compared to the Indian market.

Volatility Over Time: 524735's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19882,061Sameer Hiremathwww.hikal.com

Hikal Limited, together with its subsidiaries, manufactures and sells various chemical intermediates, specialty chemicals, and active pharma ingredients to pharmaceutical, animal health, biotech, crop protection, and specialty chemicals companies in India, the United States, Canada, Europe, South East Asia, and internationally. It operates through two segments, Pharmaceuticals and Crop Protection. The Pharmaceuticals segment produces active pharmaceutical ingredients (APIs).

Hikal Limited Fundamentals Summary

How do Hikal's earnings and revenue compare to its market cap?
524735 fundamental statistics
Market cap₹45.49b
Earnings (TTM)₹736.02m
Revenue (TTM)₹18.21b

64.1x

P/E Ratio

2.6x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
524735 income statement (TTM)
Revenue₹18.21b
Cost of Revenue₹9.02b
Gross Profit₹9.20b
Other Expenses₹8.46b
Earnings₹736.02m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)5.97
Gross Margin50.50%
Net Profit Margin4.04%
Debt/Equity Ratio64.2%

How did 524735 perform over the long term?

See historical performance and comparison

Dividends

0.3%

Current Dividend Yield

10%

Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/20 14:27
End of Day Share Price 2025/01/20 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Hikal Limited is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Rohit BhatBatlivala & Karani Securities India Pvt. Ltd.
Kameswari V. S. ChavaliFirstCall Research
Siddhant KhandekarICICIdirect.com